The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens

British Journal of Cancer

Volumn 95, Issue 9, 2006, Pages 1202-1211

  Steele, J C ^a   Torr, E E ^a   Noakes, K L ^b   Kalk, E ^a   Moss, P A ^a   Reynolds, G M ^c   Hubscher, S G ^c   Van Lohuizen, M ^d   Adams, D H ^c   Young, L S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Wellington House ^*  (United Kingdom)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cytotoxic T cell; Immunotherapy; Polycomb; Regulatory T cell; Tumour antigens

Indexed keywords

EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; EPITOPE; GAMMA INTERFERON; PROTEIN BMI 1; PROTEIN EZH 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; FIBROBLAST; HLA SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SEROLOGY; STAINING; T LYMPHOCYTE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 33750431017     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603369     Document Type: Article

References (44)

1. Altman J, Moss PAH, Goulder P, Barouch D, McHeyzer-Williams M, Bell JI, McMichael AJ, Davis M (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96
2. Bea S, Tort F, Pinyol M, Puig X, Hernandez L, Hernandez S, Fernandez PL, van Lohuizen M, Colomer D, Campo E (2001) BMI-1 gene amplification and overexpression in haematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61: 2409-2412
3. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22: 5323-5335
4. Breuer RH, Snijders PJ, Smit EF, Sutedja TG, Sewalt RG, Otte AP, van Kemenade FJ, Postmus PE, Meijer CJ, Raaphorst FM (2004) Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6: 736-743
5. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949
6. Dukers DF, van Galen JC, Giroth C, Jansen P, Sewalt RG, Otte AP, Kluin-Nelemans HC, Meijer CJ, Raaphorst FM (2004) Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 164: 873-881
7. Gilboa E (2004) The promise of cancer vaccines. Nat Rev Cancer 4: 401-411
8. Gnjatic S, Jager E, Chen W, Altorki NK, Matsuo M, Lee S-Y, Chen Q, Nagata Y, Atanackovic D, Chen Y-T (2002) CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci USA 99: 11813-11818
9. Hernandez-Munoz I, Taghavi P, Kuijl C, Neefjes J, van Lohuizen M (2005) Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1. Mol Cell Biol 25: 11047-11058
10. Jacobs JJ, van Lohuizen M (2002) Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 1602: 151-161
11. Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS, Kim JW (2004) Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 13: 383-388
12. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611
13. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AR (1997) Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 158: 3325-3334
14. Lessard J, Sauvageau G (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255-260
15. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761
16. Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA (1996) Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J Immunother Emphasis Tumor Immunol 19: 266-277
17. Miller G, Lipman M (1973) Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci USA 70: 190-194
18. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ (2003) Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425: 962-967
19. Nishikawa H, Kato T, Tawara I, Saito K, Ikeda H, Kuribayash K, Allen PM, Schreiber RD, Sakaguchi S, Old LJ, Shiku H (2005) Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J Exp Med 201: 681-686
20. Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K, Harada M (2004) Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. Prostate 60: 273-281
21. Ormandy LA, Hilleman T, Wedemeyer H, Manns MP, Greten TF, Korangy F (2005) Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65: 2457-2464
22. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152: 163-172
23. Pfreundschuh M (2000) Exploitation of the B cell repertoire for the identification of human tumour antigens. Cancer Chemother Pharmacol 46(Suppl): S3-S7
24. Raaphorst FM (2003) Self-renewal of hematopoietic and leukemic stem cells: a central role for the polycomb-group gene Bmi-1. Trends Immunol 24: 522-524
25. Raaphorst FM, Meijer CJ, Fieret E, Blokzijl T, Mommers E, Buerger H, Packeisen J, Sewalt RA, Otte AP, van Diest PJ (2003) Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5: 481-488
26. Raaphorst FM, Vermeer M, Fieret E, Blokzijl T, Dukers D, Sewalt RG, Otte AP, Willemze R, Meijer CJ (2004) Site-specific expression of polycomb-group genes encoding the HPC-HPH/PRC1 complex in clinically defined primary nodal and cutaneous large B-cell lymphomas. Am J Pathol 164: 533-542
27. Reynolds GM, Billingham LJ, Gray LJ, Flavell JR, Najafipour S, Crocker J, Nelson P, Young LS, Murray PG (2002) Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. Br J Haematol 118: 195-201
28. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411: 380-384
29. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915
30. Saleh F, Renno W, Klepacek I, Ibrahim G, Asfar S, Dashti H, Romero P, Dashti A, Behbehani A (2005) Direct evidence on the immune-mediated spontaneous regression of human cancer: an incentive for pharmaceutical companies to develop a novel anti-cancer vaccine. Curr Pharm Des 11: 3461-3473
31. Satijn DPE, Olson DJ, van der Vlag J, Hamer KM, Lambrechts C, Masselink H, Gunster MJ, Sewalt RG, van Driel R, Otte AP (1997) Interference with the expression of a novel human polycomb protein, hPc2, results in cellular transformation and apoptosis. Mol Cell Biol 17: 6076-6086
32. Satijn DPE, Otte AP (1999) RING1 interacts with multiple polycomb-group proteins and displays tumorigenic activity. Mol Cell Biol 19: 57-68
33. Schultze JL, Vonderheide RH (2001) From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol 22: 516-523
34. Sellers WR, Loda M (2002) The EZH2 polycomb transcriptional repressor - a marker or mover of metastatic prostate cancer? Cancer Cell 2: 349-350
35. Shao Z, Raible F, Mollaaghababa R, Guyon JR, Wu CT, Bender W, Kingston RE (1999) Stabilization of chromatin structure by PRC1, a polycomb complex. Cell 98: 37-46
36. Shevach EM, McHugh RS, Piccirillo CA, Thornton AM (2001) Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 182: 58-67
37. Shi YY, Wang HC, Yin YH, Sun WS, Li Y, Zhang CQ, Wang Y, Wang S, Chen WF (2005) Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br J Cancer 92: 929-934
38. Stevanovic S (2002) Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2: 514-520
39. Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, Coleman N, Alexander GJM (2005) Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41: 722-730
40. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629
41. Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ, Willemze R, Otte AP (2001) The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 112: 950-958
42. Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, van Lohuizen M, Betticher DC (2001) The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84: 1372-1376
43. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772
44. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168: 4272-4276